Table 1 Patient and transplant characteristics.

From: Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

 

MRD negative

MRD positive

Test p-value

Number

749

293

 

Follow-up (surviving patients): median (range) (IQR)

24.6 (0.5–132.5) (7.7–54.3)

26.9 (0.8–121.5) (8.2–60.4)

0.58

Age at transplant: median (range) (IQR)

49.4 (18–78.1) (37.7–58.8)

49.8 (19.5–72.9) (37.6–58.4)

0.89

Year of transplant: median (range)

2012 (2006–2016)

2012 (2006–2016)

0.31

Time from diagnosis to transplant: median (range) (IQR) m

18.2 (3–200) (13.5–27.1)

15.9 (3–200) (11.6–21.8)

<10−4

Male patients

390 (52.07%)

168 (57.34%)

0.13

Female patients

359 (47.93%)

125 (42.66%)

 

Donor male

445 (60.22%)

189 (64.73%)

0.18

Donor female

294 (39.78%)

103 (35.27%)

 

Missing

10

1

 

Female recipients and male recipients of male donors

598 (80.27%)

243 (83.22%)

0.28

Male recipients of female donors

147 (19.73%)

49 (16.78%)

 

Missing

4

1

 

KPS < 80

25 (3.49%)

8 (2.86%)

0.62

KPS > = 80

691 (96.51%)

272 (97.14%)

 

missing

33

13

 

KPS < 90

148 (21.08%)

63 (22.74%)

0.57

KPS > = 90

554 (78.92%)

214 (77.26%)

 

Missing

47

16

 

Patient CMV negative

248 (34.35%)

95 (32.76%)

0.63

Patient CMV positive

474 (65.65%)

195 (67.24%)

 

Missing

27

3

 

Donor CMV negative

331 (45.84%)

146 (51.59%)

0.10

Donor CMV positive

391 (54.16%)

137 (48.41%)

 

Missing

27

10

 

CMV donor negative/recipient negative

177 (24.96%)

71 (25.18%)

0.24

CMV donor positive/recipient negative

66 (9.31%)

23 (8.16%)

 

CMV donor negative/recipient positive

146 (20.59%)

74 (26.24%)

 

CMV donor positive/recipient positive

320 (45.13%)

114 (40.43%)

 

Missing

40

11

 

Cytogenetics

Good

193 (48.61%)

102 (53.4%)

0.18

Intermediate

188 (47.36%)

77 (40.31%)

 

Adverse

16 (4.03%)

12 (6.28%)

 

Missing

352

102

 

FLT3 negative

94 (63.09%)

66 (70.21%)

0.25

FLT3 positive

55 (36.91%)

28 (29.79%)

 

Missing

600

199

 

NPM1 negative

42 (33.6%)

31 (42.47%)

0.21

NPM1 positive

83 (66.4%)

42 (57.53%)

 

Missing

624

220

 

MSD

376 (50.2%)

134 (45.73%)

0.20

VUD HLA 10/10

373 (49.8%)

159 (54.27%)

 

MAC

430 (57.41%)

180 (61.43%)

0.24

RIC

319 (42.59%)

113 (38.57%)

 
  1. CMV cytomegalovirus, IQR interquartile range, KPS Karnofsky performance status, MAC myeloablative conditioning, MSD matched sibling donor, RIC reduced-intensity conditioning, MUD matched unrelated donor.
Back to article page